A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5494-5509

  Shen, Na ^a   Yan, Fei ^a   Pang, Jiuxia ^a   Wu, Lai Chu ^b   Al Kali, Aref ^c   Litzow, Mark R ^c   Liu, Shujun ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

DNA methylation; DNA methyltransferase; Leukemia; Nucleolin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOLIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELL CLONING; CONTROLLED STUDY; DNA METHYLATION; DNMT1 GENE; DOWN REGULATION; ENZYME INDUCTION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; MOLECULAR PATHOLOGY; MOUSE; NCL GENE; NONHUMAN; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84906244425     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2131     Document Type: Article

References (51)

1. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer cell. 2010; 17(4):333-347.
2. Tefferi A and Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(5):573-582.
3. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010; 18(6):553-567.
4. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine. 2010; 363(25):2424-2433.
5. Liu S. Epigenetics advancing personalized nanomedicine in cancer therapy. Advanced drug delivery reviews. 2012; 64(13):1532-1543.
6. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001; 97(5):1172-1179.
7. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008; 111(4):2364-2373.
8. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Ohno R, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004; 103(5):1901-1908.
9. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D and Marcucci G. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. The Journal of pharmacology and experimental therapeutics. 2007; 321(3):953-960.
10. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE and Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PloS one. 2011; 6(7):e22110.
11. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y and Maciejewski JP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009; 113(6):1315-1325.
12. Krust B, El Khoury D, Nondier I, Soundaramourty C and Hovanessian AG. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type. BMC cancer. 2011; 11:333.
13. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N and Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer research. 2008; 68(7):2358-2365.
14. Soundararajan S, Wang L, Sridharan V, Chen W, Courtenay-Luck N, Jones D, Spicer EK and Fernandes DJ. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Molecular pharmacology. 2009; 76(5):984-991.
15. Teng Y, Girvan AC, Casson LK, Pierce WM, Jr., Qian M, Thomas SD and Bates PJ. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer research. 2007; 67(21):10491-10500.
16. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK and Fernandes DJ. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007; 109(7):3069-3075.
17. Singh K, Laughlin J, Kosinski PA and Covey LR. Nucleolin is a second component of the CD154 mRNA stability complex that regulates mRNA turnover in activated T cells. J Immunol. 2004; 173(2):976-985.
18. Chen CY, Gherzi R, Andersen JS, Gaietta G, Jurchott K, Royer HD, Mann M and Karin M. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes & development. 2000; 14(10):1236-1248.
19. Wang SA, Li HY, Hsu TI, Chen SH, Wu CJ, Chang WC and Hung JJ. Heat shock protein 90 stabilizes nucleolin to increase mRNA stability in mitosis. The Journal of biological chemistry. 2011; 286(51):43816-43829.
20. Pickering BF, Yu D and Van Dyke MW. Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. The Journal of biological chemistry. 2011; 286(51):44095-44103.
21. Wei PC, Wang ZF, Lo WT, Su MI, Shew JY, Chang TC and Lee WH. A cis-element with mixed G-quadruplex structure of NPGPx promoter is essential for nucleolin-mediated transactivation on non-targeting siRNA stress. Nucleic acids research. 2013; 41(3):1533-1543.
22. Shang Y, Kakinuma S, Nishimura M, Kobayashi Y, Nagata K and Shimada Y. Interleukin-9 receptor gene is transcriptionally regulated by nucleolin in T-cell lymphoma cells. Molecular carcinogenesis. 2012; 51(8):619-627.
23. Gonzalez V, Guo K, Hurley L and Sun D. Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. The Journal of biological chemistry. 2009; 284(35):23622-23635.
24. Angelov D, Bondarenko VA, Almagro S, Menoni H, Mongelard F, Hans F, Mietton F, Studitsky VM, Hamiche A, Dimitrov S and Bouvet P. Nucleolin is a histone chaperone with FACT-like activity and assists remodeling of nucleosomes. The EMBO journal. 2006; 25(8):1669-1679.
25. Tominaga K, Srikantan S, Lee EK, Subaran SS, Martindale JL, Abdelmohsen K and Gorospe M. Competitive regulation of nucleolin expression by HuR and miR-494. Molecular and cellular biology. 2011; 31(20):4219-4231.
26. Mi Y, Thomas SD, Xu X, Casson LK, Miller DM and Bates PJ. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. The Journal of biological chemistry. 2003; 278(10):8572-8579.
27. Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, Klein JB, Pierce WM, Jr., Barve SS and Bates PJ. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Molecular cancer therapeutics. 2006; 5(7):1790-1799.
28. Zhao H, Huang Y, Xue C, Chen Y, Hou X, Guo Y, Zhao L, Hu ZH, Luo Y and Zhang L. Prognostic Significance of the Combined Score of Endothelial Expression of Nucleolin and CD31 in Surgically Resected Non-Small Cell Lung Cancer. PloS one. 2013; 8(1):e54674.
29. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, Haeseler A, Gattermann N, Haas R, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007; 21(3):494-504.
30. Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, Ishii E, Mizutani S, Imashuku S, Ohki M and Ichikawa H. Identification of a gene expression signature associated with pediatric AML prognosis. Blood. 2003; 102(5):1849-1856.
31. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S and Radich JP. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes, chromosomes & cancer. 2008; 47(1):8-20.
32. Johansson H, Svensson F, Runnberg R, Simonsson T and Simonsson S. Phosphorylated nucleolin interacts with translationally controlled tumor protein during mitosis and with Oct4 during interphase in ES cells. PloS one. 2010; 5(10):e13678.
33. Srivastava M and Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 1999; 13(14):1911-1922.
34. Gnesutta N and Minden A. Death receptor-induced activation of initiator caspase 8 is antagonized by serine/threonine kinase PAK4. Molecular and cellular biology. 2003; 23(21):7838-7848.
35. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S and Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5(12):4041-4047.
36. Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, Lu LT, Chen CH, Gu DL, Pu YS, Jou YS, Lu KP, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer cell. 2011; 20(2):214-228.
37. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Frohling S, Fleming M, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature medicine. 2010; 16(8):903-908.
38. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Buchner T, Wormann B, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008; 112(10):4193-4201.
39. Reyes-Reyes EM, Teng Y and Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer research. 2010; 70(21):8617-8629.
40. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J and Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PloS one. 2010; 5(12):e15787.
41. Ginisty H, Sicard H, Roger B and Bouvet P. Structure and functions of nucleolin. Journal of cell science. 1999; 112 ( Pt 6):761-772.
42. Rickards B, Flint SJ, Cole MD and LeRoy G. Nucleolin is required for RNA polymerase I transcription in vivo. Molecular and cellular biology. 2007; 27(3):937-948.
43. Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. The Journal of experimental medicine. 2013; 210(5):951-968.
44. Pontvianne F, Abou-Ellail M, Douet J, Comella P, Matia I, Chandrasekhara C, Debures A, Blevins T, Cooke R, Medina FJ, Tourmente S, Pikaard CS and Saez-Vasquez J. Nucleolin is required for DNA methylation state and the expression of rRNA gene variants in Arabidopsis thaliana. PLoS genetics. 2010; 6(11):e1001225.
45. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T and Saiki I. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. The Journal of biological chemistry. 2003; 278(38):36916-36923.
46. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009; 113(25):6411-6418.
47. Ireson CR and Kelland LR. Discovery and development of anticancer aptamers. Molecular cancer therapeutics. 2006; 5(12):2957-2962.
48. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(40):15805-15810.
49. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C and Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011; 333(6047):1300-1303.
50. Tsou JH, Chang KY, Wang WC, Tseng JT, Su WC, Hung LY, Chang WC and Chen BK. Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells. Nucleic acids research. 2008; 36(1):217-227.
51. Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho YY, Lee SY, Kim JE, Bode AM and Dong Z. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 2012; 72(12):3060-3068.